NEUROBIOLOGICAL TECHNOLOGIES BEGINS XERECEPT TRIALS

Neurobiological Technologies announced the enrollment of the first patients in an open-label, extended-use study of Xerecept (hCRF). This study is open to all patients who participate in one of the two ongoing, blinded, Phase III trials designed to determine the dexamethasone-sparing effects of hCRF in brain tumor patients being treated for peritumoral brain edema.

This extended-use program will collect safety information and allow the treating physicians to attempt a maximum dexamethasone reduction and possible elimination altogether. Xerecept will be provided to patients until either the drug becomes commercially available or NTI research in this indication is discontinued.